What is Lifesci Capital’s Estimate for CRBP Q1 Earnings?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Stock analysts at Lifesci Capital boosted their Q1 2025 EPS estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Tuesday, March 11th. Lifesci Capital analyst M. Belghiti now anticipates that the biopharmaceutical company will post earnings per share of ($2.74) for the quarter, up from their prior estimate of ($2.95). The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. Lifesci Capital also issued estimates for Corbus Pharmaceuticals’ Q2 2025 earnings at ($3.00) EPS, Q3 2025 earnings at ($3.28) EPS, Q4 2025 earnings at ($3.59) EPS and FY2025 earnings at ($12.62) EPS.

A number of other research firms also recently weighed in on CRBP. Jefferies Financial Group cut their price target on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating on the stock in a report on Tuesday. William Blair initiated coverage on shares of Corbus Pharmaceuticals in a report on Friday, February 28th. They set an “outperform” rating on the stock. Piper Sandler initiated coverage on shares of Corbus Pharmaceuticals in a research note on Monday, December 2nd. They issued an “overweight” rating and a $35.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price (down from $75.00) on shares of Corbus Pharmaceuticals in a research note on Wednesday. Finally, StockNews.com upgraded shares of Corbus Pharmaceuticals to a “sell” rating in a research note on Thursday, March 6th. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $59.13.

Corbus Pharmaceuticals Trading Down 7.1 %

Corbus Pharmaceuticals stock opened at $6.42 on Friday. The company has a market capitalization of $78.19 million, a P/E ratio of -1.37 and a beta of 2.63. The firm’s fifty day simple moving average is $9.56 and its 200-day simple moving average is $19.35. Corbus Pharmaceuticals has a 1-year low of $6.38 and a 1-year high of $61.90.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.24.

Institutional Trading of Corbus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of CRBP. Vestcor Inc acquired a new stake in Corbus Pharmaceuticals in the 3rd quarter worth $64,000. Wells Fargo & Company MN grew its position in Corbus Pharmaceuticals by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 2,195 shares during the last quarter. Avanza Fonder AB acquired a new stake in Corbus Pharmaceuticals in the 4th quarter worth $84,000. Deutsche Bank AG boosted its position in shares of Corbus Pharmaceuticals by 46.8% during the 4th quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 2,616 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Corbus Pharmaceuticals during the 4th quarter valued at about $101,000. 64.64% of the stock is currently owned by institutional investors and hedge funds.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.